KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial (Q43250046)
Jump to navigation
Jump to search
scientific article published on 2 November 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial |
scientific article published on 2 November 2009 |
Statements
1 reference
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial (English)
1 reference
1 reference
Susan D Richman
1 reference
Matthew T Seymour
1 reference
Philip Chambers
1 reference
Faye Elliott
1 reference
Catherine L Daly
1 reference
Angela M Meade
1 reference
Graham Taylor
1 reference
2 November 2009
1 reference
1 reference
Identifiers
1 reference